Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2009 1
2010 3
2011 1
2012 4
2013 6
2014 3
2015 4
2016 10
2017 6
2018 5
2019 5
2020 5
2021 8
2022 6
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Results by year

Filters applied: . Clear all
Page 1
Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: Looking for new tumor biological fingerprints.
Fanale D, Corsini LR, Bono M, Randazzo U, Barraco N, Brando C, Cancelliere D, Contino S, Giurintano A, Magrin L, Pedone E, Perez A, Piraino P, Pivetti A, Giovanni ED, Russo TDB, Prestifilippo O, Gennusa V, Pantuso G, Russo A, Bazan V. Fanale D, et al. Crit Rev Oncol Hematol. 2024 Jan;193:104220. doi: 10.1016/j.critrevonc.2023.104220. Epub 2023 Nov 29. Crit Rev Oncol Hematol. 2024. PMID: 38036154 Review.
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?
Incorvaia L, Perez A, Marchetti C, Brando C, Gristina V, Cancelliere D, Pivetti A, Contino S, Di Giovanni E, Barraco N, Bono M, Giurintano A, Bazan Russo TD, Gottardo A, Cutaia S, Pedone E, Peri M, Corsini LR, Fanale D, Galvano A, Scambia G, Badalamenti G, Russo A, Bazan V. Incorvaia L, et al. Among authors: fanale d. Cancer Treat Rev. 2023 Dec;121:102650. doi: 10.1016/j.ctrv.2023.102650. Epub 2023 Oct 31. Cancer Treat Rev. 2023. PMID: 37939446 Free article. Review.
Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer.
Fanale D, Brando C, Corsini LR, Cutaia S, Di Donna MC, Randazzo U, Filorizzo C, Lisanti C, Magrin L, Gurrera V, Romano R, Dimino A, Bazan Russo TD, Olive D, Vieni S, Pantuso G, Giordano A, Chiantera V, Russo A, Bazan V, Iovanna JL. Fanale D, et al. BMC Cancer. 2023 May 13;23(1):437. doi: 10.1186/s12885-023-10911-5. BMC Cancer. 2023. PMID: 37179293 Free PMC article.
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay.
Incorvaia L, Rinaldi G, Badalamenti G, Cucinella A, Brando C, Madonia G, Fiorino A, Pipitone A, Perez A, Li Pomi F, Galvano A, Gristina V, Barraco N, Bono M, Bazan Russo TD, Toia F, Cordova A, Fanale D, Russo A, Bazan V. Incorvaia L, et al. Among authors: fanale d. Ther Adv Med Oncol. 2023 Feb 15;15:17588359231151845. doi: 10.1177/17588359231151845. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36818688 Free PMC article.
Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?
Fanale D, Corsini LR, Brando C, Cutaia S, Di Donna MC, Filorizzo C, Lisanti MC, Randazzo U, Magrin L, Romano R, Bazan Russo TD, Olive D, Vieni S, Pantuso G, Chiantera V, Russo A, Bazan V, Iovanna JL. Fanale D, et al. Front Oncol. 2022 Sep 21;12:946319. doi: 10.3389/fonc.2022.946319. eCollection 2022. Front Oncol. 2022. PMID: 36212445 Free PMC article.
MUTYH-associated tumor syndrome: The other face of MAP.
Magrin L, Fanale D, Brando C, Corsini LR, Randazzo U, Di Piazza M, Gurrera V, Pedone E, Bazan Russo TD, Vieni S, Pantuso G, Russo A, Bazan V. Magrin L, et al. Among authors: fanale d. Oncogene. 2022 Apr;41(18):2531-2539. doi: 10.1038/s41388-022-02304-y. Epub 2022 Apr 14. Oncogene. 2022. PMID: 35422474 Review.
BRCA1/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: Looking for the hidden meaning.
Fanale D, Pivetti A, Cancelliere D, Spera A, Bono M, Fiorino A, Pedone E, Barraco N, Brando C, Perez A, Guarneri MF, Russo TDB, Vieni S, Guarneri G, Russo A, Bazan V. Fanale D, et al. Crit Rev Oncol Hematol. 2022 Apr;172:103626. doi: 10.1016/j.critrevonc.2022.103626. Epub 2022 Feb 10. Crit Rev Oncol Hematol. 2022. PMID: 35150867 Review.
70 results